On August 6, 2026, the FDA extended its DSCSA exemption for small dispensers, pushing the deadline from November 27, 2026 to November 27, 2027 (1). A small dispenser is a pharmacy whose owning company has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians, counted as of November 27, 2026. The extra time lets FDA finish its required assessment of small dispensers’ package-level tracing capabilities, including a survey it asked small dispensers to complete by September 22, 2026, a public comment period on the final report and a public meeting on the findings (1).
If you're a small pharmacy, that headline probably landed as good news. And it is — but not in the way a lot of people are about to assume.
What does the small dispenser exemption actually cover?
The exemption covers only certain enhanced drug distribution security requirements: exchanging transaction information electronically and interoperably, including package-level product identifiers, the related electronic verification and response systems, and product identifier checks on a set share of suspect product (1). Everything else in Section 582 still applies.
Here's the trap: "exemption" sounds like "off the hook." It isn't. The FDA has been explicit, in this announcement and the ones before it, that the relief is narrow. It applies to specific enhanced drug distribution security (EDDS) requirements — mainly the obligation to exchange transaction data electronically, at the package level, using interoperable systems (EPCIS). It is not a blanket exemption from Section 582 of the FD&C Act, and it is not a delay of DSCSA itself.
That distinction matters because a meaningful list of DSCSA duties were never part of the exemption to begin with. They've applied all along, exemption or not — and they're exactly the kind of thing an auditor or regulator will ask about.
What DSCSA requirements do small dispensers still have to meet?
Small dispensers must still buy only from Authorized Trading Partners, keep transaction information and statements for six years, quarantine and investigate suspect product, notify FDA and trading partners within 24 hours of finding illegitimate product, and answer regulator requests for tracing information within 2 business days (2). Manual methods are fine for now. Here’s the full list:
- Buy only from Authorized Trading Partners. Purchasing from state-licensed wholesalers and FDA-registered manufacturers or repackagers is a foundational §582 duty. It was never on the exemption list.
- Obtain and retain product tracing information for six years, and produce it on request. The exemption covers how you're allowed to collect that data (manual methods are fine for now) — not whether you have to have it. If you don't have a repository building right now, you're already behind on a six-year retention clock.
- Identify, quarantine, and investigate suspect product under documented SOPs. Manual methods are permitted, but the SOPs themselves — and the obligation to actually follow them — are not exempted.
- Verify suspect product with the manufacturer and notify trading partners. The exemption covers verifying the product identifier on the statutorily designated share of suspect or illegitimate packages, plus electronic, package-level verification systems (1). Every other verification step in Section 582(d)(4), including the investigation itself and notifying trading partners, still applies.
- Report illegitimate product to FDA within 24 hours using Form 3911, and notify trading partners (2) (3). Not exempted, full stop.
- Respond to a regulator’s request for tracing information within 2 business days. When FDA or a state official asks for transaction information during a recall or a suspect or illegitimate product investigation, dispensers must provide it within 2 business days (2). The exemption lets you gather that data with current, manual methods. It does not change the deadline.
- Maintain SOPs for suspect product identification, data-to-product accuracy checks, and partner registration verification. Still required.
- Match physical product to its data and flag discrepancies to the sender. The reconciliation duty persists regardless of exemption status.
None of this requires the electronic, interoperable EPCIS infrastructure that big distributors and manufacturers have had to build. But it does require having answers ready — in writing, on demand — for every item above.
Should small pharmacies wait until 2027 to comply?
No. The extension only delays electronic, interoperable tracing, and FDA says it should not be viewed as a reason to delay implementation (1). The rest of a small pharmacy’s DSCSA duties apply today, and a regulator’s request for tracing information comes with a 2-business-day deadline whether or not the pharmacy is exempt.
The FDA’s own framing of the extension is telling: it’s giving itself time to run an assessment, publish findings, and hold a public meeting. The letter also says the exemption is no reason to delay, and it strongly urges small dispensers to keep implementing the enhanced requirements (1).
The 2-business-day response window is the one that tends to catch people off guard. If a state board or FDA investigator asks for tracing records and your SOPs, quarantine logs, and ATP verification aren’t already organized, two business days is not enough time to build them from scratch.
How does Pharmacy Pro cover each requirement?
We built OneScan Pharmacy Pro’s compliance modules around this exact list, because it’s the list that determines what actually gets checked.
DSCSA requirements still in force for small dispensers, and how Pharmacy Pro covers them
| Requirement in force now |
Pharmacy Pro coverage |
| Buy only from Authorized Trading Partners |
ATP module: auto-verifies and manages partner licenses via NABP Pulse + MedPro |
| Retain 6 years of T3/EPCIS tracing data, produce on request |
EPCIS module: 6-year retention repository, building now |
| Quarantine and investigate suspect product |
SOP module: documented quarantine and investigation procedures |
| Verify suspect/illegitimate product, notify partners |
VRS module: electronic verification, faster than manual processes |
| Report illegitimate product to FDA within 24 hours (2) |
3911 module: auto-fill and tracking for Form 3911 |
| Respond to regulator requests within 2 business days (2) |
Reporting module: produces tracing documentation on demand |
| Maintain SOPs for suspect product, data accuracy, partner registration |
SOP module + automated ATP/registration checks |
| Match physical product to data, flag discrepancies |
Enhanced Supply Chain Security: automated matching and discrepancy notification |
The bottom line
The 2027 extension buys small dispensers real time on the hardest, most expensive part of DSCSA compliance: full electronic interoperability. It doesn't touch the rest. If your pharmacy is treating this extension as a reason to wait, the gap between “exempt” and “compliant” is exactly where an audit will find you.
Get audit-ready before your next DSCSA request
OneScan Pharmacy Pro brings Authorized Trading Partner checks, six-year record retention, suspect product workflows and Form 3911 reporting into one system for independent and small pharmacies. See how Pharmacy Pro works or browse our resources for dispensers.
Sources